Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RBM-007 Injectable · 1 trial · 1 indication
Biomicroscopy is used by an ophthalmologist to assess the health of the front of the eye. The measure is the number of subjects with abnormal findings that were not present at screening.
Ophthalmoscopy is used by an ophthalmologist to assess the health of the back of the eye. The measure is the number of subjects with abnormal findings that were not present at screening.
| Arm | Type | Description |
|---|---|---|
| RBM-007 Injectable Solution - 0.2 mg | EXPERIMENTAL | No additional information. |
| RBM-007 Injectable Solution - 1.0 mg | EXPERIMENTAL | No additional information. |
| RBM-007 Injectable Solution - 2.0 mg | EXPERIMENTAL | No additional information. |
| Name | Type | Description |
|---|---|---|
| RBM-007 Injectable Solution | DRUG | (No additional description) |
Inclusion Criteria: 1. Male or female 55 years of age or older on the date of signing the informed consent form and able and willing to comply with all treatment and follow-up study procedures. 2. At Screening Visit, subjects must meet all the following inclusion criteria: 3. Must have had prior tr...
RBM-007 Injectable is an investigational small molecule being developed for the treatment of Age-related Macular Degeneration (AMD), specifically exudative AMD. It is administered via injection and is currently in Phase 1 clinical development.
RBM-007 Injectable is being developed by BrainsWay Ltd. (NASDAQ: BWAY). The company is conducting clinical trials to evaluate the safety and efficacy of this investigational therapy for Age-related Macular Degeneration.
RBM-007 Injectable is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational, meaning it has not yet been approved by regulatory authorities for commercial use.
RBM-007 Injectable has been studied in one completed Phase 1 clinical trial, NCT03633084, titled 'RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration.' This trial enrolled 9 participants in the United States and included patients aged 55 years and older.
Yes, RBM-007 Injectable is the same drug as RBM-007. The name 'RBM-007 Injectable' specifies the route of administration, while 'RBM-007' is the core drug name used in clinical trial documentation.